Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SABSW SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM)
0.060-0.007-10.45%
Close
02/03 16:00 ET
High
0.060
Open
0.060
Turnover
60.00
Low
0.060
Pre Close
0.067
Volume
986.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
SAB Biotherapeutics Gets Additional $8.2M in Funding in Closeout DoD Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Received An Additional $8.2M From DoD Related To Closeout Of The Discontinued COVID-19 Prototype Research And Development Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Received An Additional $8.2M From DoD Related To Closeout Of The Discontinued COVID-19 Prototype Research And Development Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing With
SAB Biotherapeutics' CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
SIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
EXCLUSIVE: SAB Biotherapeutics Provides Q3 Company Update, Says Received $8.6M From DoD Contract On Nov. 10 For Work Performed
EXCLUSIVE: SAB Biotherapeutics Provides Q3 Company Update, Says Received $8.6M From DoD Contract On Nov. 10 For Work Performed
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Presents Overview Of DiversitAb Platform And Data Showing Benefits Of Fully-Human Polyclonal Antibodies Derived From Cows Vs. Human-Derived Plasma At 2022 Plasma Product Biotechnology Conference
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Presents Overview Of DiversitAb Platform And Data Showing Benefits Of Fully-Human Polyclonal Antibodies Derived From Cows vs. Human-Derived Plasma At
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associ
Company Overview
More
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton and is headquartered in Sioux Falls, SD.
CEO： Dr. Eddie J. Sullivan, PhD
Market： NASDAQ
Listing Date： 02/09/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet